Ann Pediatr Endocrinol Metab Search


Ann Pediatr Endocrinol Metab > Volume 28(3); 2023 > Article
Lee, Kim, Yoon, Hwang, Kim, Yoo, and Choi: Clinical outcomes and genotype-phenotype correlations in patients with complete and partial androgen insensitivity syndromes



Androgen insensitivity syndrome (AIS) is a rare X-linked recessive disorder caused by unresponsiveness to androgens because of mutations in the AR gene. Here, we investigated the clinical outcomes and molecular spectrum of AR variants in patients with AIS attending a single academic center.


This study included 19 patients with AIS who were confirmed by molecular analysis of AR. Clinical features and endocrinological findings were retrospectively collected, including presenting features, external genitalia, sex of rearing, timing of gonadectomy, pubertal outcomes, and sex hormone levels. Molecular analysis of AR was performed using Sanger, targeted gene panel, or whole-exome sequencing.


Among all 19 patients, 14 (74%) were classified as having complete AIS (CAIS), whereas 5 (26%) had partial AIS (PAIS). All patients with CAIS, and 3 patients with PAIS were reared as female. One patient with CAIS manifested a mixed germ cell tumor at the age of 30 years. Molecular analysis of AR identified 19 sequence variants; 12 (63%) were previously reported, and the remaining 7 (37%) were novel. Missense mutations were the most common type (12 of 19, 63%), followed by small deletions, nonsense mutations, an insertion, and a splice site mutation.


Here, we describe the clinical outcomes and molecular characteristics of 19 Korean patients with AIS. Patients with PAIS manifested various degrees of masculinization of the external genitalia. Nonsense and frameshift mutations were frequent in patients with CAIS, whereas patients with PAIS harbored exclusively missense mutations.


· Patients with partial androgen insensitivity syndrome (PAIS) exhibited various degrees of ambiguous external genitalia ranging from predominantly female to undervirilized male phenotypes. Molecular analysis of AR identified 19 mutations, including 7 novel sequence variants. Nonsense and frameshift mutations were frequent in patients with complete androgen insensitivity syndrome, whereas patients with PAIS harbored exclusively missense mutations.


Androgen insensitivity syndrome (AIS) is an X-linked recessively inherited disorder caused by complete or partial unresponsiveness to androgens in individuals with a 46,XY karyotype because of mutations in the AR gene [1]. In 1953, Morris et al. first described testicular feminization syndrome in 82 females with bilateral testes, which was subsequently renamed "complete AIS (CAIS) [2]."
Patients with CAIS typically present with either inguinal hernia in the infantile period or primary amenorrhea in the adolescent period [3]. Development of estrogen-dependent secondary sexual characteristics, such as breast development, occurs as a result of excess aromatization of androgens; however, pubic or axillary hairs are usually absent or sparse. Partial AIS (PAIS) refers to phenotypes that include varying degrees of masculinization of the external genitalia because of partial androgen responsiveness, resulting in clitoromegaly, cryptorchidism, micropenis, hypospadias, or bifid scrotum [2]. For patients with PAIS, sex assignment is based on the external genitalia [4]. Due to an absence of the uterus, patients with AIS do not menstruate and are infertile. Mild AIS (MAIS) is generally associated with typical male genitalia in individuals presenting with gynecomastia or infertility in later life.5
The AR protein is a 110 kDa, 919–amino acid protein composed of the following 4 major functional domains: the N-terminal domain (NTD) encoded by exon 1, the central DNA-binding domain (DBD) encoded by exons 2 and 3, a C-terminal ligand-binding domain (LBD) encoded by exons 4–8, and a hinge region connecting the LBD to the DBD [2]. The NTD contains the activation function-1 region, which plays a pivotal role in transactivation of AR and regulates the interactions with the LBD [1]. The activation function-2 region is located in the LBD and is important for stabilizing the entire protein structure, allowing interaction between the NTD region and specific coregulators [6].
To date, >400 mutations in AR have been reported in the Androgen Receptor Gene Mutations Database ( Among them, missense mutations are the most common, followed by nonsense mutations, deletions, insertions, and splice site mutations [7]. Nonsense mutations and small insertions and deletions causing frameshifts that lead to premature stop codons are more common in patients with CAIS than in those with PAIS [8]. Further, mutations that partially interfere with AR function manifest clinically as PAIS [1].
There have been only a few case reports of AIS in Korea [9-11], and the long-term outcomes of patients with AIS have not been described in this context. Thus, we conducted this study to investigate the clinical outcomes and molecular spectrum in patients with AIS attending a single academic center.

Materials and methods

1. Subjects

This study included 19 consecutive patients with AIS diagnosed from January 2004 to May 2022 at the Department of Pediatrics, Asan Medical Center, Seoul, Korea. Per the study inclusion criteria for AIS patients, eligible individuals had a 46,XY karyotype confirmed by molecular analysis of AR. AIS was classified as either CAIS or PAIS according to clinical manifestations. Patients who had complete female external genitalia with testes located in the inguinal or abdominal area or patients who presented with primary amenorrhea and breast development as well as sparse to absent pubic hair during puberty were classified as having CAIS. Patients with ambiguous genitalia, such as male-like external genitalia with cryptorchidism, micropenis, hypospadias, or female-like external genitalia with clitoromegaly, were classified as having PAIS [2]. Seven previously reported patients with AIS were included to allow delineation of the clinical and molecular spectra in the full cohort of AIS patients [12-14].

2. Clinical and endocrinological evaluations

Patient clinical parameters were retrospectively collected, including presenting features, sex of rearing, timing of gonadectomy, and pubertal outcomes. Height and weight were expressed as standard deviation scores based on Korean reference data [15]. Pubertal stage was rated according to the Marshall and Tanner criteria [16]. External genitalia were assessed using the Prader stage or external masculinization score [17].
Endocrine functions were analyzed, including serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, testosterone (T), and dihydrotestosterone (DHT). A human chorionic gonadotropin (hCG) stimulation test was performed in 12 patients to evaluate Leydig cell function. Serum T and DHT levels were measured at baseline and on the fourth day after consecutive intramuscular injections of hCG (IVF-C, LG Chemistry, Seoul, Korea) at 1,000 units/day for 3 days. Serum T level was measured by radioimmunoassay (Coat-A-Count, Diagnostic Products, Los Angeles, CA, USA). The response to hCG was regarded as positive if the T level increased to at least twice the baseline value [18]. Pelvic ultrasound or magnetic resonance imaging was performed to investigate Müllerian duct remnants.

3. Molecular analysis of the AR gene

The AR gene was sequenced by either Sanger (n=14), targeted gene panel (n=3), or whole-exome sequencing (WES) (n=2) methods. Genomic DNA was extracted from peripheral blood leukocytes using the Gentra Puregene DNA isolation kit (Qiagen, Hilden, Germany). For Sanger sequencing, 8 exons of AR and their exon-intron boundaries were amplified by polymerase chain reaction, using specific oligonucleotide primers. Polymerase chain reaction products were directly sequenced using an ABI3130x1 genetic analyzer (Applied Biosystems, Foster City, CA, USA), as previously described [12]. Target gene panel sequencing was performed using a customized panel including 67 genes previously reported as associated with disorders of sex development in humans, as previously described [13]. For WES, SureSelect Human All Exon V5 (Agilent Technologies, Santa Clara, CA, USA) was used for library preparation. Sequencing was performed using the NextSeq500 platform (Illumina Inc., San Diego, CA, USA), generating 2 × 150-bp paired-end reads. Sequence reads were aligned to the human reference genome (hg19) using the Burrows-Wheeler Alignment program (version 0.7.12, The SAMtools 0.1.19 and Genome Analysis toolkits (version 3.5, were used for single-nucleotide polymorphism variant calling from aligned sequence reads. The Genome Analysis toolkit version 3.5, FreeBayes, and Scalpel-0.5.3 were used for insertion–deletion variant calling. After removing duplicates with PICARD (version 1.96,, annotation was performed with Variant Effect Predictor19) and dbNSFP [20].
Sequence variants were classified according to the standards and guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology [21], and those identified by targeted gene panel sequencing or WES were validated by Sanger sequencing.

4. Ethical statement

This study was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB no. 2021-1728). DNA analysis was performed after obtaining written informed consent from patients or their guardians.


1. Clinical and endocrine characteristics of AIS at presentation and clinical outcomes

Among all 19 patients included in this study, 14 (74%) were classified as having CAIS, while the remaining 5 (26%) had PAIS. The clinical characteristics of the 19 patients with AIS are summarized in Table 1 and Fig. 1. The median follow-up duration was 4 years (range, 3 months to 17 years; Table 1). All patients with CAIS were raised as females. Among 5 patients with PAIS, 3 were raised as female, and the other 2 (patients 2 and 11) were assigned male at birth (Table 1). No patients have presented with gender identity problems to date.
Five patients with CAIS presented with primary amenorrhea at the age of 18.4±4.2 years (range, 13–25 years) and showed breast development to Tanner stage III–V; however, there was no pubic hair development. Among these 5 patients with CAIS, patient No. 4 manifested primary amenorrhea but did not visit the hospital. At the age of 30 years, she was referred to our institute because of abdominal pain and was diagnosed with a mixed germ cell tumor of the gonad, which required surgery and chemotherapy.
Seven patients with CAIS were brought to the hospital because of inguinal hernia at the age of 8.8±6.7 months (range, 3 days to 19 months). Six of them (patient Nos. 5, 6, 10, 13, 16, and 18) underwent bilateral inguinal herniorrhaphy at the age of 9.1±7.2 months (range, 1–19 months), whereas the remaining patient (No. 12) was lost to follow-up.
The remaining 2 patients with CAIS presented during the neonatal period: patient No. 9 was referred because of palpable gonads in the labia majora, and patient No. 17, who had female external genitalia, was referred to our clinic because of a 46,XY karyotype detected by G-scanning (MGmed, Seoul, Korea), a genetic screening test performed to detect chromosomal abnormalities using a microarray. Both intra-abdominal testes were detected in patient No. 17 by magnetic resonance imaging.
Patients with PAIS presented at a median age of 2 years (range, 4 days to 3 years) because of clitoromegaly (n=3), ambiguous genitalia (n=1), hypospadias (n=2), micropenis (n=2), or inguinal hernia (n=1). Patient No. 1, who was raised as female, presented with clitoromegaly at 2 months of age and underwent gonadectomy and clitoroplasty at the age of 4 years. Patient No. 2 presented with hypospadias and inguinal gonads at the age of 4 days. Orchiopexy was performed at the age of 12 months, and repair of hypospadias was conducted at the age of 3.5 years. His stretched penile length was 2 cm at 5 years old. Two patients with PAIS (patient Nos. 7 and 15), who were reared as female, underwent bilateral inguinal herniorrhaphy during the infant period. Patient No. 11 presented with micropenis and hypospadias at the age of 3 years and underwent repair of hypospadias. He was lost to follow-up after surgery and visited the outpatient clinic at the age of 19 years because of delayed puberty and gynecomastia and has been treated with monthly testosterone enanthate since.
Following hCG stimulation, all 12 patients tested showed elevated serum T level compared to baseline (Table 2). Five patients with CAIS (patient Nos. 3, 4, 8, 12, and 16) showed high LH and FSH levels, suggesting hypergonadotropic hypogonadism; patient No. 12 was 3 months old when the hormone tests were conducted, while the remaining 4 patients (patient Nos. 3, 4, 8, and 16) were 19±7.8 years old when the test was performed.
Nine patients (47%) underwent gonadectomy at a median age of 7 years (range, 5 months to 30 years), and 7 of them had CAIS. Four patients with CAIS (patient Nos. 3, 4, 8, and 19) underwent prophylactic gonadectomy after pubertal age (22.3±6.3 years; range, 15–30 years). Three patients with CAIS (patient Nos. 9, 13, and 17) underwent gonadectomy at a median age of 14 months (range, 5–22 months). Patient No. 9 showed testes protruding toward the labia majora and underwent orchiectomy with labiaplasty at the age of 5 months. Patient No. 13 underwent gonadectomy during inguinal herniorrhaphy at the age of 14 months. Patient No. 17 underwent gonadectomy at the age of 22 months before being diagnosed with CAIS by WES. Two patients with PAIS (patient Nos. 1 and 7, both reared as female) underwent gonadectomy during clitoroplasty at 4 and 7 years of age, respectively.
Four patients with CAIS (patient Nos. 3, 8, 13, and 19) and 2 patients with PAIS (patient Nos. 1 and 7), who were reared as female, have been treated with estrogen replacement therapy since the median age of 14±8.8 years (range, 11–33 years).
Bone mineral density (BMD) analysis was performed in one patient (patient No. 3) at the age of 34 years, which revealed BMD z-scores of the femur neck and spine of -2.2 and -3.1 points, respectively. She has been treated with denosumab at a dose of 60 mg every 6 months.

2. Mutation spectrum of the AR gene and genotypephenotype correlations

Nineteen mutations were identified in the 19 patients, with no mutation hotspots (Table 3, Fig. 2). Missense mutations were the most common (12 of 19, 63%), followed by small deletions (n=3), nonsense mutations (n=2), an insertion (n=1), and a splice site mutation (n=1). Mutations were maternally inherited in 7 patients (37%), while the remaining 12 patients did not undergo family testing. Family testing was performed in 2 female siblings of patients 9 and 18 and revealed normal sequences of AR.
Twelve patients (63%) harbored previously known pathogenic or likely pathogenic variants, while novel sequence variants were identified in the remaining 7 patients (37%), including c.1337dup (p.L446Ffs*56), c.2440del (p.F814Sfs*9), c.2327T>A (p.M776K), c.2353T>G (p.C785G), c.1768+1G>A, c.2380G>T (p.E794*), and c.2182del (p.N728Tfs*61). Six of the novel variants were classified as pathogenic or likely pathogenic using American College of Medical Genetics and Genomics criteria (Table 3). The remaining novel variant (p.M776K) was a variant of uncertain significance; however, it was predicted to be deleterious by in silico prediction programs and not found in the Genome Aggregation Database (, suggesting that it was the pathogenic cause of AIS.
The patients with CAIS harbored 7 missense mutations, 3 small deletions, 2 nonsense mutations, 1 insertion, and 1 splice site mutation. Two mutations (p.Q76* and p.L446Ffs*56) were located in the NTD, 3 (p.R616del, p.R616H, and c.1768+1G>A) were located in the DBD, and 9 (p.N728Tfs*61, p.M776K, p.E794*, p.C785G, p.F814Sfs*9, p.F828L, p.R841C, p.R841H, and p.L882P) were located in the LBD. Meanwhile, all 5 patients with PAIS harbored exclusively missense mutations in the LBD (n=3) or DBD (n=2).


Here, we describe the clinical outcomes and mutation spectrum in a relatively large cohort of patients with AIS in Korea. The major phenotypes observed among patients with CAIS in this study were inguinal hernia in infancy or primary amenorrhea during puberty. Patients with PAIS exhibited various degrees of ambiguous external genitalia ranging from predominantly female to undervirilized male phenotypes, which may be attributable to residual AR function.
As patients with AIS are resistant to androgens, basal T and LH levels tend to be elevated because of a lack of negative feedback inhibition from the anterior pituitary gland [2]. Further, FSH level is usually normal because testicular inhibin B secretion is not impeded [2]. In the present study, no significant differences in hormone levels, including those determined by hCG stimulation testing, were detected between patients with CAIS and PAIS, consistent with findings of a previous report [8].
Patients with CAIS are at an increased risk for gonadal cancer [22]. Decreased AR activity and abnormal gonadal location can influence the survival of atypical germ cells, leading to histopathologic changes [23]. Gonadal tumors are rare in pediatric populations, where malignancy rates are low, ranging from 0.8%–2.0% [24,25]; however, rates up to 22% have been reported in adults with CAIS [26]. In patients with PAIS, the gonads can be preserved for endogenous hormone function or fertility potential; therefore, the incidence of germ cell tumor is significantly high (up to 15%) [27]. For patients with AIS raised female, bilateral gonadectomy is recommended to avoid virilization and reduce the risk of gonadal tumors [27,28]. In the consensus statement on the management of disorders of sex development, gonadectomy should be performed in patients with CAIS and PAIS; however, there is no recommendation for the timing of gonadectomy [25]. Recommendations have been made to perform gonadectomy after puberty in patients with CAIS to induce spontaneous puberty [2]. As the risk of gonadal germ cell tumor before puberty is very low, it is reasonable to delay gonadectomy until adulthood [22]. In the present study, seven of 14 patients with CAIS and 3 of 5 patients with PAIS did not undergo gonadectomy. However, these patients have remained under surveillance for gonadal germ cell tumors by annual ultrasound. After gonadectomy, sex hormone replacement therapy is required to induce secondary sexual characteristics and promote psychosocial well-being and bone health [3], and this therapy should be administered until the age of natural menopause, with regular monitoring of BMD. In patients who wish to preserve their gonads, annual ultrasonography or magnetic resonance imaging of gonads is recommended [8]. In the present study, only one patient with CAIS (patient No. 4) developed a mixed germ cell tumor at the age of 30 years as the first presenting feature. Hence, early diagnosis and regular monitoring of patients with AIS are critical to prevent malignant gonadal tumors.
Infertility is a major issue associated with AIS. AIS patients raised female are infertile because they do not have a uterus. Although fertility is challenging for individuals with PAIS reared as male, there are a few cases of successful fertility achieved in men with PAIS using assisted conception techniques [29].
In the present study, all 19 patients with AIS harbored private mutations. To our knowledge, there have been no reports on racial differences in the mutation spectrum. Missense mutations were the most common in this study, consistent with previous studies [1,7]. Splice site mutations and large deletions spanning several exons are typically observed in <10% of patients [1]. Most mutations causing both CAIS and PAIS are located in the LBD, followed by the NTD and DBD [7]. More than half of all AR mutations are located in the LBD, and the majority of these is missense mutations, whereas approximately 20% of mutations are located in the NTD [30]. Exon 1 is the largest exon of AR and has a GC-rich region, which makes it difficult to sequence. Therefore, the mutation frequencies in exon 1 could be underestimated, given that the length of the NTD totals more than half of the AR gene [30], suggesting that systematic sequencing of exon 1 is necessary. Mutations in the NTD are more frequent in CAIS, whereas defects in the LBD are more common in PAIS [8]. Almost all AR mutations in MAIS are found in the NTD; however, the number of AR mutations related to this phenotype is small [8]. Of mutations in the NTD encoded by exon 1, 71% are nonsense or frameshift mutations causing CAIS, while only 29% are missense mutations, which are primarily associated with PAIS or MAIS [1].
Two patients with CAIS (patient Nos. 6 and 12) and one patient with PAIS (patient No. 2) harbored a hemizygous mutation of AR inherited from their mothers, who were diagnosed with polycystic ovary syndrome (PCOS). The mutations were c.2482T>C (p.F828L), c.2353T>G (p.C785G), and c.1789G>A (p.A597T), respectively. Previous studies have suggested that heterozygous AR variants are associated with PCOS or hyperandrogenism [31]. Nucleotide changes in AR may promote PCOS progression [32]. In addition, the number of CAG repeats in the region of AR encoding the NTD is inversely correlated with AR activity, and patients with PCOS tend to have lower mean CAG repeat numbers than controls [33].
This study has several limitations. First, some clinical data and endocrinological findings, such as external masculinization score, family history, hCG stimulation test results, obesity, BMD, and quality of life, were not available for all patients because of the retrospective study design. In addition, the follow-up periods and intervals used to identify long-term outcomes differed among individuals. Second, molecular analysis of AR was performed using different methods, including Sanger sequencing, targeted panel sequencing, or WES, depending on availability. Nevertheless, we describe the clinical and molecular characteristics of a relatively large cohort of Korean patients with AIS.
In conclusion, this study describes data on the long-term clinical outcome and molecular characteristics of 19 Korean patients with AIS. Molecular analysis of AR identified 19 mutations, including 7 novel sequence variants. Nonsense and frameshift mutations were frequent in patients with CAIS, whereas patients with PAIS harbored exclusively missense mutations. Patients with PAIS manifested various degrees of masculinization of the external genitalia. Early diagnosis and regular follow-up, as well as timely sex hormone replacement therapy, are required to prevent gonadal cancer and to improve quality of life.


Conflicts of interest

No potential conflicts of interest relevant to this article are reported.


This study was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) (no. NRF2021R1F1A104593011).

Data availability

The datasets used and/or analyzed for this study are available from the corresponding author upon reasonable request.

Author contribution

Conception or design: NYL and JHC. Acquisition, analysis, or interpretation of data: NYL, JHK, JHY, SH, GHK, HWY, and JHC. Drafting or revising the work: NYL and JHC. Final approval of the manuscript: NYL, JHK, JHY, SH, GHK, HWY, and JHC.

Fig. 1.
Sex of rearing and pubertal outcomes of patients with androgen insensitivity syndrome. AIS, androgen insensitivity syndrome.
Fig. 2.
Mutation spectrum of the AR gene. Molecular analysis of AR identified 19 mutations among 19 patients, including 7 novel sequence variants (bold). AIS, androgen insensitivity syndrome; NTD, N-terminal transactivation domain; DBD, DNA-binding domain; LBD, ligand-binding domain.
Table 1.
Clinical characteristics of patients with androgen insensitivity syndrome at presentation and timing of gonadectomy
Patient No. Diagnosis Presenting features Gonad position, right/left Prader stage/EMS Sex of rearing Age at presentation/diagnosis Height SDS Weight SDS Breast Tanner stage (left/right) Timing of gonadectomy Current age Follow-up duration
1 PAIS Clitoromegaly Inguinal/inguinal I/2 F 2 mo/3 yr 0.78 1.45 II/I 4 yr 20 yr 17 yr
2 PAIS Ambiguous genitalia, hypospadias Inguinal/inguinal II/3 M 4 days/2 yr -0.99 -1.18 NA ND 5 yr 3 yr
3 CAIS Primary amenorrhea Inguinal/inguinal I/2 F 19 yr/20 yr -0.01 0.57 n.i. 24 yr 35 yr 15 yr
4 CAIS Primary amenorrhea Mixed germ cell tumor in the pelvic cavity I/n.i. F 25 yr/31 yr 0.78 0.30 n.i. 30 yr 32 yr 1 yr
5 CAIS Inguinal hernia Abdomen/abdomen I/1 F 12 mo/3 yr 0.79 0.83 NA ND 6 yr 3 yr
6 CAIS Inguinal hernia Inguinal/inguinal I/2 F 8 mo/10 mo -0.06 0.46 IV/IV ND 13 yr 12 yr
7 PAIS Inguinalhernia, clitoromegaly Inguinal/inguinal I/2 F 12 mo/7 yr 2.09 1.11 II/II 7 yr 13 yr 6 yr
8 CAIS Primary amenorrhea Inguinal/inguinal I/2 F 15 yr/15 yr 2.13 0.20 III/II 15 yr 26 yr 11 yr
9 CAIS Prominent labia majora Labia majora/labia majora I/3 F 2 mo/4 mo 4.14 2.08 III/III 5 mo 12 yr 11 yr
10 CAIS Inguinal hernia Dissected/scrotum I/n.i. F 1 mo/12 mo 2.00 1.31 II/II ND 7 yr 6 yr
11 PAIS Micropenis, hypospadias, gynecomastia Scrotum/scrotum IV/5 M 3 yr/19 yr -0.52 2.32 I/I* ND 21 yr 2 yr
12 CAIS Inguinal hernia Inguinal/inguinal I/2 F n.i./3 mo 3.03 0.86 NA ND 19 mo 1.3 yr
13 CAIS Inguinal hernia No visible testes I/0 F 13 mo/10 yr 1.37 0.58 III/III 14 mo 14 yr 4 yr
14 CAIS Primary amenorrhea Inguinal/inguinal I/2 F 13 yr/13 yr 1.30 0.40 IV/IV ND 18 yr 6 yr
15 PAIS Clitoromegaly Inguinal/inguinal I/2 F 1 mo/7 mo -0.13 -0.09 NA ND 5 yr 5 yr
16 CAIS Inguinal hernia Inguinal/inguinal I/2 F 3 days/12 yr 0.85 1.45 IV/ IV ND 14 yr 2 yr
17 CAIS Cryptorchidism Abdomen/abdomen I/1 F n.i./4 yr 1.80 1.77 NA 22 mo 5 yr 1 yr
18 CAIS Inguinal hernia Inguinal/inguinal I/2 F 19 mo/20 mo 2.19 1.73 NA ND 33 mo 1.1 yr
19 CAIS Primary amenorrhea n.i. I/n.i. F 20 yr/34 yr 0.49 3.22 V/V 20 yr 34 yr 3 mo

EMS, external masculinization score; SDS, standard deviation score; PAIS, partial androgen insensitivity syndrome; CAIS, complete androgen insensitivity syndrome; n.i., not informative; NA, not assessed; ND, not done.

* The patient underwent bilateral mastectomy for gynecomastia before visiting our institute.

Table 2.
Endocrinologic findings of patients with androgen insensitivity syndrome
Patient No. Diagnosis Age at test Basal testosterone (ng/mL) hCG-stimulated testosterone (ng/mL) LH (IU/L) FSH (IU/L) Estradiol (pg/mL)
1 PAIS 3 yr 0.13 0.89* <2.0 <2.0 ND
2 PAIS 3 mo 0.98 4.17* 1.7 4.3 ND
3 CAIS 19 yr 1.2 ND 14.4* 68.5* 28.2
4 CAIS 30 yr 0.99 ND 38.9* 77.9* 37.6
5 CAIS 24 mo 0.21 1.77* 0.79 1.14 17.7
6 CAIS 9 mo 2.5* 8* 3.3 1.0 25.
7 PAIS 7 yr 0.04 0.98* 0.45 3.6 30.8
8 CAIS 15 yr 8.1 ND 18.0* 4.0 46.4
9 CAIS 4 mo 0.15 5.8* 1.1 3.5 18.1
10 CAIS 12 mo 0.93* 9.8* 5.4* 4.0 10.0
11 PAIS 19 yr 19.0 ND 10.7* 3.7 36.6
12 CAIS 3 mo ND ND 21.14* 5.43 <5.0
13 CAIS 18 mo 0.35 4.0* 0.93 7.1 10
14 CAIS 13 yr 15.6 22.2* 5.9 6.7 4
15 PAIS 7 mo 0.25 11.4* 0.62 1.8 4.0
16 CAIS 12 yr 5.5 6.4* 8.7* 4.9 4
17 CAIS 5 mo 3.2* 25.0* 1.4 0.53 10.0
18 CAIS 20 mo 0.1 ND 0.58 8.4 4.0
19 CAIS 23 yr 0.46 ND 30.4* 56.0* 100.5

hCG, human chorionic gonadotropic hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; PAIS, partial androgen insensitivity syndrome; CAIS, complete androgen insensitivity syndrome; ND, not done.

* Higher than the age-related reference range.

Table 3.
Mutations in AR in patients with androgen insensitivity syndrome and prediction of protein function
Patient No. Diagnosis Nucleotide change Amino acid change Location Inheritance PolyPhen-2 scorea) SIFT scoreb) CADD scorec) MAF from gnomAD browser (%)d) ACMG guideline Reference
1 PAIS c.2110A>G p.S704G Exon 4 NA 1.000 0.04 23.8 ND LP Li et al. [34] 2015
2 PAIS c.1789G>A p.A597T Exon 3 Maternal 0.295 0.05 26.6 ND Pathogenic Deeb et al. [35] 2005
3 CAIS c.1337dup p.L446Ffs*56 Exon 1 NA NA NA NA ND Pathogenic Novel
4 CAIS c.1847_1849del p.R616del Exon 3 NA NA NA NA ND LP Beitel et al. [36] 1994
5 CAIS c.1847G>A p.R616H Exon 3 NA 1.000 0.00 28.3 0.0005467 Pathogenic Beitel et al. [36] 1994
6 CAIS c.2482T>C p.F828L Exon 7 Maternal 1.000 0.01 23.1 ND LP Nam et al. [31] 2015
7 PAIS c.2696T>A p.I899N Exon 8 NA 1.000 0.00 28.6 ND LP Hiort et al. [37] 1996
8 CAIS c.2440del p.F814Sfs*9 Exon 6 NA NA NA NA ND Pathogenic Novel
9 CAIS c.2521C>T p.R841C Exon 7 Maternal 1.000 0.01 23.4 ND Pathogenic Wang et al. [38] 2005
10 CAIS c.2327T>A p.M776K Exon 6 Maternal 0.946 0.00 26.9 ND VUS Novel
11 PAIS c.2229G>A p.M743I Exon 5 NA 0.921 0.02 26.4 ND LP Audi et al. [39] 2010
12 CAIS c.2353T>G p.C785G Exon 6 Maternal 1.000 0.01 24.5 ND LP Novel
13 CAIS c.1768+1G>A Splice site Intron 2 NA NA NA 33 ND LP Novel
14 CAIS c.2522G>A p.R841H Exon 7 NA 1.000 0.01 23.5 ND Pathogenic Kohler et al. [40] 2005
15 PAIS c.1706G>A p.G569E Exon 2 Maternal 1.000 0.00 26.2 ND LP Audi et al. [39] 2010
16 CAIS c.2645T>C p.L882P Exon 8 NA 1.000 0.00 28.5 ND LP Galani et al. [41] 2008
17 CAIS c.226C>T p.Q76* Exon 1 NA NA NA 29.9 ND Pathogenic Audi et al. [39] 2010
18 CAIS c.2380G>T p.E794* Exon 6 Maternal NA NA 40 ND Pathogenic Novel
19 CAIS c.2182del p.N728Tfs*61 Exon 5 NA NA NA NA ND Pathogenic Novel

SIFT, sorting intolerant from tolerant; CADD, combined annotation-dependent depletion; MAF, minor allele frequency; gnomAD, genome aggregation database; ACMG, American College of Medical Genetics; PAIS, partial androgen insensitivity syndrome; CAIS, complete androgen insensitivity syndrome; NA, not assessed; ND, not detected; LP, likely pathogenic; VUS, variant of uncertain significance.

a) PolyPhen-2 scores: <0.15 points, benign; >0.15 points, possibly damaging; >0.85 points, probably damaging.

b) SIFT score: <0.05 points, predicted to be deleterious.

c) Threshold for pathogenesis, scaled C-score (Phred score) ≥10 points.

d) Minor allele frequency values of variants in the general population were determined using the Genome Aggregation Database (


1. Hornig NC, Holterhus PM. Molecular basis of androgen insensitivity syndromes. Mol Cell Endocrinol 2021;523:111146.
crossref pmid
2. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet 2012;380:1419–28.
crossref pmid
3. Bertelloni S, Dati E, Baroncelli GI, Hiort O. Hormonal management of complete androgen insensitivity syndrome from adolescence onward. Horm Res Paediatr 2011;76:428–33.
crossref pmid pdf
4. Boehmer AL, Brinkmann O, Brüggenwirth H, van Assendelft C, Otten BJ, Verleun-Mooijman MC, et al. Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab 2001;86:4151–60.
crossref pmid
5. Yong EL, Loy CJ, Sim KS. Androgen receptor gene and male infertility. Hum Reprod Update 2003;9:1–7.
crossref pmid
6. Chang CY, McDonnell DP. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 2002;16:647–60.
crossref pmid
7. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database: 2012 update. Hum Mutat 2012;33:887–94.
crossref pmid
8. Batista RL, Costa EMF, Rodrigues AS, Gomes NL, Faria JA Jr, Nishi MY, et al. Androgen insensitivity syndrome: a review. Arch Endocrinol Metab 2018;62:227–35.
crossref pmid pmc
9. Heo YJ, Ko JM, Lee YA, Shin CH, Yang SW, Kim MJ, et al. Two Korean girls with complete androgen insensitivity syndrome diagnosed in infancy. Ann Pediatr Endocrinol Metab 2018;23:220–5.
crossref pmid pmc pdf
10. Lee SW, Kwak DS, Jung IS, Kwak JH, Park JH, Hong SM, et al. Partial androgen insensitivity syndrome presenting with gynecomastia. Endocrinol Metab 2015;30:226–30.
crossref pmid pmc
11. Lee KH, Lim YJ, Lee JS, Kim MS, Jo JH, Kim KR, et al., editors. A case of complete androgen insensitivity syndrome with malignant mixed germ cell tumors. Korean J Obstet Gynecol 2011;54:701–6.
12. Choi JH, Kim GH, Seo EJ, Kim KS, Kim SH, Yoo HW. Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development. J Pediatr Endocrinol Metab 2008;21:545–53.
crossref pmid
13. Kim JH, Kang E, Heo SH, Kim GH, Jang JH, Cho EH, et al. Diagnostic yield of targeted gene panel sequencing to identify the genetic etiology of disorders of sex development. Mol Cell Endocrinol 2017;444:19–25.
crossref pmid
14. Choi JH, Lee Y, Oh A, Kim GH, Yoo HW. Molecular characteristics of sequence variants in GATA4 in Patients with 46,XY disorders of sex development without cardiac defects. Sex Dev 2019;13:240–5.
crossref pmid pdf
15. Kim JH, Yun S, Hwang SS, Shim JO, Chae HW, Lee YJ, et al. The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr 2018;61:135–49.
crossref pmid pmc pdf
16. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.
crossref pmid pmc
17. Ahmed SF, Khwaja O, Hughes IA. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int 2000;85:120–4.
crossref pmid
18. Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z, et al. Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (Revised 2015). Clin Endocrinol 2016;84:771–88.

19. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The ensembl variant effect predictor. Genome Biol 2016;17:122.
crossref pmid pmc
20. Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum Mutat 2016;37:235–41.
crossref pmid pmc
21. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.
crossref pmid pmc pdf
22. Patel V, Casey RK, Gomez-Lobo V. Timing of gonadectomy in patients with complete androgen insensitivity syndromecurrent recommendations and future directions. J Pediatr Adolesc Gynecol 2016;29:320–5.
crossref pmid
23. Hannema SE, Scott IS, Rajpert-De Meyts E, Skakkebaek NE, Coleman N, Hughes IA. Testicular development in the complete androgen insensitivity syndrome. J Pathol 2006;208:518–27.
crossref pmid
24. Cools M, Drop SL, Wolffenbuttel KP, Oosterhuis JW, Looijenga LH. Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 2006;27:468–84.
crossref pmid pdf
25. Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on management of intersex disorders. Arch Dis Child 2006;91:554–63.
crossref pmid pmc
26. Deans R, Creighton SM, Liao LM, Conway GS. Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence. Clin Endocrinol 2012;76:894–8.
27. Cools M, Looijenga LH, Wolffenbuttel KP, T'Sjoen G. Managing the risk of germ cell tumourigenesis in disorders of sex development patients. Endocr Dev 2014;27:185–96.
crossref pmid
28. Barros BA, Oliveira LR, Surur CRC, Barros-Filho AA, Maciel-Guerra AT, Guerra-Junior G. Complete androgen insensitivity syndrome and risk of gonadal malignancy: systematic review. Ann Pediatr Endocrinol Metab 2021;26:19–23.
crossref pmid pmc pdf
29. Lucas-Herald A, Bertelloni S, Juul A, Bryce J, Jiang J, Rodie M, et al. The long-term outcome of boys With partial androgen insensitivity syndrome and a mutation in the androgen receptor gene. J Clin Endocrinol Metab 2016;101:3959–67.
crossref pmid pmc
30. Gottlieb B, Beitel LK, Trifiro MA. Variable expressivity and mutation databases: The androgen receptor gene mutations database. Hum Mutat 2001;17:382–8.
crossref pmid
31. Nam H, Kim CH, Cha MY, Kim JM, Kang BM, Yoo HW. Polycystic ovary syndrome woman with heterozygous androgen receptor gene mutation who gave birth to a child with androgen insensitivity syndrome. Obstet Gynecol Sci 2015;58:179–82.
crossref pmid pmc
32. Wang F, Pan J, Liu Y, Meng Q, Lv P, Qu F, et al. Alternative splicing of the androgen receptor in polycystic ovary syndrome. Proc Natl Acad Sci U S A 2015;112:4743–8.
crossref pmid pmc
33. Peng CY, Xie HJ, Guo ZF, Nie YL, Chen J, Zhou JM, et al. The association between androgen receptor gene CAG polymorphism and polycystic ovary syndrome: a casecontrol study and meta-analysis. J Assist Reprod Genet 2014;31:1211–9.
crossref pmid pmc pdf
34. Li Y, Qu S, Li P. A novel mutation of the androgen receptor gene in familial complete androgen insensitivity syndrome. Eur Rev Med Pharmacol Sci 2015;19:4146–52.
35. Deeb A, Mason C, Lee YS, Hughes IA. Correlation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome. Clin Endocrinol 2005;63:56–62.
36. Beitel LK, Prior L, Vasiliou DM, Gottlieb B, Kaufman M, Lumbroso R, et al. Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptor. Hum Mol Genet 1994;3:21–7.
37. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K. The clinical and molecular spectrum of androgen insensitivity syndromes. Am J Med Genet 1996;63:218–22.
crossref pmid
38. Wang M, Wang J, Zhang Z, Zhao Z, Zhang R, Hu X, et al. Dissecting phenotypic variation among AIS patients. Biochem Biophys Res Commun 2005;335:335–42.
crossref pmid
39. Audi L, Fernandez-Cancio M, Carrascosa A, Andaluz P, Toran N, Piro C, et al. Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development. J Clin Endocrinol Metab 2010;95:1876–88.
crossref pmid
40. Kohler B, Lumbroso S, Leger J, Audran F, Grau ES, Kurtz F, et al. Androgen insensitivity syndrome: somatic mosaicism of the androgen receptor in seven families and consequences for sex assignment and genetic counseling. J Clin Endocrinol Metab 2005;90:106–11.
crossref pmid pdf
41. Galani A, Sofocleous C, Karahaliou F, Papathanasiou A, Kitsiou-Tzeli S, Kalpini-Mavrou A. Sex-reversed phenotype in association with two novel mutations c.2494delA and c.T3004C in the ligand-binding domain of the androgen receptor gene. Fertil Steril 2008;90:2008.e1–4.
crossref pmid


Browse all articles >

Editorial Office
501-107, 30 Seocho-daero 74-gil, Seocho-gu, Seoul 06622, Republic of Korea
Tel: +82-2-3471-4268    Fax: +82-2-3471-4269    E-mail:                

Copyright © 2023 by Korean Society of Pediatric Endocrinology.

Developed in M2PI

Close layer
prev next